Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Zydus Lifesciences's net income from continuing operations for the
three
months ended in Mar. 2026 was ₹13,410 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2026 was ₹51,235 Mil.
Zydus Lifesciences Net Income From Continuing Operations Historical Data
* Premium members only.
The historical data trend for Zydus Lifesciences's Net Income From Continuing Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zydus Lifesciences Net Income From Continuing Operations Chart
Zydus Lifesciences Net Income From Continuing Operations Calculation
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹51,235 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Income From Continuing Operations of ₹51,235 Mil mean?
Zydus Lifesciences (NSE:ZYDUSLIFE) has a Net Income From Continuing Operations of ₹51,235 Mil as of Mar. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Zydus Lifesciences and its competitors.
Is Zydus Lifesciences' Net Income From Continuing Operations too high?
Zydus Lifesciences' current Net Income From Continuing Operations is ₹51,235 Mil. Overall, Zydus Lifesciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zydus Lifesciences' Net Income From Continuing Operations compare to ZTS?
Zydus Lifesciences' Net Income From Continuing Operations of ₹51,235 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Drug Manufacturers company?
A good Net Income From Continuing Operations depends on the Drug Manufacturers industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Zydus Lifesciences and its competitors. Zydus Lifesciences's current Net Income From Continuing Operations is ₹51,235 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zydus Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Zydus Lifesciences (NSE:ZYDUSLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,144.12, compared to a current price of ₹1,112.20 — trading 2.8% below its estimated fair value. The current Net Income From Continuing Operations is ₹51,235 Mil. Zydus Lifesciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Zydus Lifesciences (NSE:ZYDUSLIFE), the current Net Income From Continuing Operations is ₹51,235 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zydus Lifesciences (NSE:ZYDUSLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Zydus Lifesciences stock appears to be undervalued.
The current stock price of ₹1,112.20 is trading 2.8% below its estimated GF Value™ of ₹1,144.12.
GuruFocus considers Zydus Lifesciences to be Fairly Valued.
Key valuation signals for NSE:ZYDUSLIFE:
Net Income From Continuing Operations: ₹51,235 Mil
GF Value™: ₹1,144.12 vs. price of ₹1,112.20 (2.8% below fair value)
No single metric tells the full story. See the NSE:ZYDUSLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
94GF Score
Get the complete analysis for NSE:ZYDUSLIFE
Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZYDUSLIFE has been successfully added to your 
